EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape

Na Li, Qiong Gao, Huijun Jia, Guoqing Xue, Yuanzhang Zhou, Shengnan Wang, Suxian Ma, Bingjin Hu, Zhuoyue Zhao, Chen Su, Yinghong Liu, Wenxuan Xi und 5 weitere

Journal of Clinical Investigation · 15.07.2026 · 136 (14)

DOI: 10.1172/jci198270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.06.2026. Verfasst von Na Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Sirtuin 2, Tumor Escape, B7-H1 Antigen, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Institutes of Health grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB), including PD-1/PD-L1 inhibitors, has transformed cancer therapy but benefits only a subset of patients. Understanding how PD-L1 is regulated and identifying strategies to overcome resistance remain critical. Here, we identify SIRT2 as a key positive regulator of PD-L1 across multiple human cancers. Unexpectedly, SIRT2 did not act at the transcriptional level but stabilized PD-L1 protein by preventing ubiquitin-mediated degradation. Mechanistically, SIRT2 maintained the protein stability of USP22, a PD-L1 deubiquitinase. Loss of SIRT2 reduced USP22 levels, whereas ectopic USP22 fully rescued PD-L1 expression and reversed the enhanced antitumor immunity induced by SIRT2 inhibition. We further show that SIRT2 directly deacetylates USP22 at K382 and K505 within its catalytic domain, promoting USP22 deubiquitinase activity and protecting both itself and its substrates from degradation. Our findings reveal a molecular mechanism by which an acetylation–deacetylation switch dynamically regulates deubiquitinase catalytic activity. Therapeutically, SIRT2 inhibition synergized with PD-1/PD-L1 blockade and USP22 inhibition to enhance antitumor immunity. Consistently, protein, but not mRNA, levels of SIRT2, USP22, and PD-L1 positively correlated in human bladder cancer and melanoma. Together, these findings define a SIRT2/USP22/PD-L1 axis driving tumor immune evasion and highlight SIRT2 as a promising target to improve ICB efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 2Tumor EscapeB7-H1 AntigenUbiquitin ThiolesteraseThiolester HydrolasesNeoplasm ProteinsHumansAnimalsMiceAcetylationProtein Stability

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyOncology

Substanzen

Sirtuin 2Usp22 protein, humanB7-H1 AntigenUbiquitin ThiolesteraseCD274 protein, humanSIRT2 protein, humanThiolester HydrolasesNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, China.
  • Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Immunology, College of Basic Medical Science.
  • Dalian College of Pharmacy, and.
  • Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
  • Department of Molecular Medicine, Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health grants
  • the National Natural Science Foundation of China
  • Dalian High-Level Talent Innovation Support Program

Zitieren

APA

Li, N., Gao, Q., Jia, H., Xue, G., Zhou, Y., Wang, S., Ma, S., Hu, B., Zhao, Z., Su, C., Liu, Y., Xi, W., Li, Z., Zhang, D. D., Chu, P., Sun, Z., & Fang, D. (2026). SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape. Journal of Clinical Investigation, 136(14). https://doi.org/10.1172/jci198270

Vancouver

Li N, Gao Q, Jia H, Xue G, Zhou Y, Wang S, et al. SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape. Journal of Clinical Investigation. 2026;136(14). doi:10.1172/jci198270

BibTeX
@article{Li2026,
  author = {Li, Na and Gao, Qiong and Jia, Huijun and Xue, Guoqing and Zhou, Yuanzhang and Wang, Shengnan and Ma, Suxian and Hu, Bingjin and Zhao, Zhuoyue and Su, Chen and Liu, Yinghong and Xi, Wenxuan and Li, Zhonghao and Zhang, Donna D and Chu, Peng and Sun, Zhaolin and Fang, Deyu},
  title = {SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {14},
  doi = {10.1172/jci198270}
}
Kostenlos starten →